"I want to share my story and help others like myself living with MPN. MPN Research Foundation has been that source of community support for my family and I as we learn to deal with living with a disease on a daily basis."

News

Help me find

Sanofi-Aventis purchases TargeGen, developer of drugs for Myeloproliferative Disorders

TargeGen, producer of JAK2 inhibitor TG101348, was purchased on June 30 2010 by French pharmaceutical company Sanofi-Aventis. Sanofi-Aventis hopes to continue to develop drugs targeted at hematological malignancies. Clinical trials for TG101348 have completed enrollment.

For the full press release click here.

 

Your donation goes a long way.

Learn more about how you can help support the MPN Research Foundation and the impact your contributions can make.

Donate Now
 
 
 

Subscribe

Want to learn more about the MPN Research Foundation? Sign up for our Newsletter and Research Alerts!

Newsletter Signup

 
 

Connect with Us

MPN Research Foundation wants to hear from you. Connect with us through our social networks or send us an email.

Email Facebook Twitter LinkedIn